Stem Cell Therapeutics Announces Presentations at the American Stroke Association's International Stroke Conference 2010

CALGARY, ALBERTA--(Marketwire - February 24, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) announced today several presentations that will be made on behalf of SCT during the American Stroke Association's International Stroke Conference 2010 ("ISC 2010"), February 24-26 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

Drs. Steven C. Cramer of the University of California, Irvine, CA, and Michael D. Hill of the Foothills Medical Centre at the University of Calgary, AB, co-Principal Investigators of the Phase IIb acute ischemic stroke trial, will be presenting the modified REGENESIS Phase IIb protocol and study design on Wednesday.

Additionally, Dr. Ludmila Belayev of the Louisiana State University Health Sciences Center in New Orleans, LA, will be presenting animal stroke data with growth factors, such as human Chorionic Gonadotropin, improving long-term outcomes when administered the first few days after stroke.

SCT will also be hosting a Focus Group meeting on Wednesday evening at the ISC 2010 for neurologists, clinicians, study nurses and other attendees of the Conference to listen to presentations by Drs. Steven C. Cramer and Michael D. Hill.

Visit Stem Cell Therapeutics at Booth No. 702 at the ISC 2010.

About the International Stroke Conference 2010;

(http://strokeconference.americanheart.org/portal/strokeconference/sc/): The American Stroke Association, a division of the American Heart Association, and the Stroke Council Program Committee have established a multi-year goal to reduce death and disability from stroke by 25 percent by the year 2010. The scientific and clinical content presented at this Conference provides the basis for the American Stroke Association's ongoing professional education programs. The program emphasizes basic, clinical and translational sciences as they evolve toward a more complete understanding of stroke pathophysiology with the overall goal of developing more effective prevention and treatment. The International Stroke Conference provides unique opportunities to meet with colleagues from around the world with wide-ranging research interests and expertise in stroke prevention, diagnosis, treatment and rehabilitation. Last year's professional attendance was the second highest in the conference's history. This year, attendance is expected to be more than 3,500 professionals, as well as exhibitors displaying new stroke products and services.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.